MOTS-c: what the research shows

What MOTS-c is

MOTS-c is a 16-residue peptide whose coding sequence sits inside the mitochondrial genome, in the region that encodes the 12S ribosomal RNA. The name is an acronym for mitochondrial open reading frame of the 12S rRNA type-c. It was described in 2015, and it belongs to a small class now called mitochondrial-derived peptides: short peptides encoded by mitochondrial DNA rather than nuclear DNA, of which humanin, from the 16S rRNA region, was the first to be characterised. Before that class was found, the mitochondrial genome was assumed to encode only the thirteen respiratory-chain proteins plus its own tRNAs and rRNAs.

Because the gene is mitochondrial, MOTS-c is polymorphic across mitochondrial haplogroups; one variant common in populations of East Asian descent has been examined in population-genetic work, and it is a reason different cohorts sometimes report different findings. The material sold under the name is the synthetic reference sequence, made by solid-phase synthesis.

MOTS-c is small and it circulates. It has been measured in plasma and in skeletal muscle, and its levels are reported to change with age and metabolic state in the observational studies covered below. That hormone-like behaviour is why it is discussed as a signal from the mitochondria to the rest of the cell, and to other tissues, rather than as a structural part of the organelle.

The mechanism the literature proposes

The mechanistic work is cell-culture based and builds a single story. MOTS-c is reported to inhibit the folate cycle at the step that carries one-carbon units, which lowers de-novo purine synthesis and causes the intermediate AICAR to accumulate. AICAR is an endogenous activator of AMP-activated protein kinase, so the downstream readout in those experiments is AMPK activation, with the changes in glucose uptake and fatty-acid handling that AMPK activation ordinarily produces in a myotube or an adipocyte. The folate-methionine cycle link is what distinguishes MOTS-c from other AMPK activators.

A second line reports that under metabolic stress in culture, such as glucose restriction or oxidative stress, MOTS-c moves from the cytoplasm into the nucleus and associates with stress-responsive transcription factors and antioxidant-response elements. In that framing the peptide is a retrograde signal: the mitochondrion telling the nucleus what to transcribe. The translocation has been shown in cell lines; how much it contributes to whole-animal effects is not settled.

The phrase exercise mimetic attaches to MOTS-c because those pathways overlap with the ones exercise engages, and because plasma levels of the peptide rise after a bout of exercise in the human observational work. It is a hypothesis about mechanism, and it belongs in that box. Nothing in the literature demonstrates that the peptide reproduces the effects of exercise in a person.

What the preclinical and observational studies covered

The animal work is mostly in mice. The most-cited design is diet-induced obesity: mice on a high-fat diet, with and without the peptide, followed for body weight, fat mass, glucose tolerance, insulin sensitivity and AMPK signalling in skeletal muscle. The same group and others have used aged mice, comparing running capacity, grip strength and metabolic measures across young, middle-aged and old animals, and ovariectomised mice as a model of post-menopausal metabolic change. Insulin resistance in these studies is produced by diet rather than genetics.

Tissue-level work concentrates on skeletal muscle: myotube cultures and muscle from treated animals examined for glucose uptake, mitochondrial gene expression, fibre-type markers and the folate-cycle intermediates described above. Bone, heart and adipose tissue each have a smaller number of papers, and that work is early with fewer replications.

The human work is observational, not interventional. Studies have measured circulating MOTS-c across ages, in people with and without metabolic disease, and before and after an exercise bout, reporting correlations with age, fitness and metabolic markers. A correlation in a cohort is a different kind of evidence from a treatment effect, and it is not evidence that giving the peptide to someone would do anything. Every study here is a mouse, cell or cohort study; none establishes an effect in a person.

Clinical status: CB4211 and what MOTS-c is not

One MOTS-c analogue has entered human trials. CB4211, developed by CohBar, is a modified version of the sequence that went through a Phase 1a and 1b programme, the latter in participants with obesity and non-alcoholic fatty liver disease. The programme reported top-line results in 2021 and the company did not advance the compound; as of this writing there is no MOTS-c or MOTS-c analogue in late-stage development and none has a marketing authorisation anywhere.

That is worth stating plainly, because catalogue language sometimes blurs it. MOTS-c itself has never been an approved drug, an investigational product with a completed efficacy trial, or a candidate with any regulatory designation. The CB4211 work is evidence that a company found the mechanism interesting enough to fund a first-in-human study of a related molecule, and that is all it is evidence of. Anyone reading a claim that MOTS-c is clinically proven for anything is reading a claim that the literature does not support.

Why it sits with NAD+ and SS-31

Our catalogue groups MOTS-c under longevity with NAD+ and SS-31, and the grouping is mechanistic. All three are studied in the context of mitochondrial function and its decline with age, but they touch different parts of the system. NAD+ is the coenzyme that the electron-transport chain and the sirtuin family depend on, and the research question around it is what happens when its cellular pool falls. SS-31, also called elamipretide, is a four-residue peptide that binds cardiolipin in the inner mitochondrial membrane and is studied for its effect on the structure and efficiency of the respiratory chain. MOTS-c is a signal that the mitochondrion sends outward, acting through AMPK and nuclear transcription rather than inside the organelle.

An investigator working on mitochondrial ageing therefore has three distinct handles: substrate supply, membrane structure and retrograde signalling. That is the reason the three appear together in longevity research programmes and in our research-area overview at /research/longevity/. It is not a suggestion that they are used together, and there is no controlled evidence on any combination of them in people.

Sizes, storage and reconstitution

We stock MOTS-c in 10 mg and 40 mg vials, both lyophilised powder in a sealed vial from the same manufacturer with the same certificate. The difference is the amount of material, and the choice is a question of how much a study needs across its planned runs; a larger vial costs less per milligram but only helps if the material is used within the working life of the solution. The calculator at /tools/peptide-calculator/ turns a vial mass and a diluent volume into a concentration so the two sizes can be compared for a given plan.

Keep unopened vials refrigerated, or frozen for storage beyond a few months, dry and out of light. Lyophilised peptide is hygroscopic, so let a cold vial reach room temperature before opening it; opening it cold pulls condensation onto the powder. Reconstitute with bacteriostatic water, added slowly down the inside wall of the vial, then swirl gently until the solution is clear. Do not shake. In solution, store at 2 to 8 C, avoid repeated freeze-thaw, and discard anything that has turned cloudy or shows particulates.

Diluent volume, the resulting concentration and everything downstream of that is protocol and is deliberately not on this page. The reported protocol for MOTS-c, including a concentration table computed from the vial masses we actually ship, is at /protocols/mots-c-40mg/.

Reading the certificate for a MOTS-c lot

Pure North commissioned Canada Peptide Testing, as a paying client. Published reports for this product: 40 mg vial, CPT-MOTS-40-091226 (99.74% area purity; 42.20 mg measured content). Read the original documents at /lab-results/.

The published Canada Peptide Testing reports measure RP-HPLC-UV area purity and content. They do not include mass-spectrometry identity, endotoxin, water content or a related-substances breakdown. These results do not establish clinical safety or regulatory approval.

Match the compound, vial size and printed lot to the report before relying on it. An assigned reference is not automatically the batch code on a vial. If they differ, email purenorthpeptides@proton.me with the vial details and report number to confirm the connection. Do not extend a report to another size or lot.

Regulatory status in Canada

MOTS-c is supplied in Canada as a research-use-only laboratory reference standard. It is not approved by Health Canada for any use in people, it carries no Drug Identification Number or Natural Product Number, and no MOTS-c product is an authorised therapeutic anywhere. That is the category the material sits in, and it constrains what we can say: no health claims and no outcomes. The schedules that do appear on the protocol page are a summary of what the literature reports, not a recommendation, and they carry the same research-use framing as this page.

Every order requires a research-use declaration at checkout confirming that the material is for laboratory research. That is the buyer's side of the same category.

This page is general information, not legal advice. Classification is compound-specific and can change, Health Canada is the authority, and our overview of the research-use framework is at /library/are-research-peptides-legal-in-canada/.

Frequently asked

What is MOTS-c?

MOTS-c is a 16-residue peptide encoded in the 12S ribosomal RNA region of mitochondrial DNA, described in 2015. It belongs to the mitochondrial-derived peptide class alongside humanin. It is supplied as a research-use-only laboratory reference standard made by chemical synthesis.

What has MOTS-c been studied for?

The preclinical work is in mice and cell culture: diet-induced obesity and insulin-resistance models, aged mice in treadmill and grip-strength protocols, and skeletal-muscle cultures examined for AMPK signalling, glucose uptake and folate-cycle intermediates. The human work is observational, measuring circulating levels across age, fitness and metabolic state. None of it is a treatment study in people, and no MOTS-c product has approval for any indication.

Is MOTS-c an exercise mimetic?

That is a hypothesis, not an established property. The label comes from an overlap between the pathways MOTS-c engages in cell and mouse studies, principally AMPK, and the pathways exercise engages, plus observational reports that circulating levels rise after an exercise bout. No study has shown the peptide reproduces the effects of exercise in a person.

Which MOTS-c vial size should a lab choose?

The 10 mg and 40 mg vials are the same material from the same manufacturer; the difference is the quantity. Choose by how much material the study needs across its planned runs and how quickly it will be used once in solution, since a larger vial only saves money if the contents are used before the solution ages out. The calculator at /tools/peptide-calculator/ lets you compare the two sizes for a given diluent volume.

Is MOTS-c legal in Canada?

It is sold as a research-use-only laboratory reference standard, a category distinct from products approved for human use. It is not approved by Health Canada and carries no DIN or NPN, and buyers sign a research-use declaration at checkout. Classification can change; confirm your own position with Health Canada rather than with a supplier's website.

Referenced in our catalog